Kamada Announces Binding MOU With Kedrion For The Amendment And Extension Of US Distribution Agreement For KEDRAB; Within First Four Years, Kedrion Will Purchase Minimum Quantities Of KEDRAB With Revenues To Kamada Of $180M
Portfolio Pulse from Benzinga Newsdesk
Kamada Ltd. has announced a binding Memorandum of Understanding (MOU) with Kedrion Biopharma for amending and extending their US distribution agreement for KEDRAB, a rabies immune globulin. Under the new terms, Kedrion commits to purchasing minimum quantities of KEDRAB, ensuring revenues of $180 million to Kamada over the first four years.
December 06, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kamada Ltd. has solidified its revenue stream from KEDRAB through an extended distribution agreement with Kedrion, guaranteeing $180 million in sales over the next four years.
The binding MOU with Kedrion Biopharma is a significant positive development for Kamada, as it provides a clear and substantial revenue source for the coming years. This agreement is likely to be viewed favorably by investors, as it reduces uncertainty around the company's financial outlook and demonstrates the demand for KEDRAB. The guaranteed revenue of $180 million enhances the stability of Kamada's financial projections and is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100